MedTrace Logo

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

NCT03364725 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-12-07

No results posted yet for this study

Summary

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants.

Conditions

  • Hepatitis C
  • Addict Heroin

Interventions

DRUG

Glecaprevir-pibrentasvir

Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Id Care

    lead OTHER

Principal Investigators

  • Ronald Nahass, MD · Id Care

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2018-09-01
Completion
2019-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03364725 on ClinicalTrials.gov